A strong tailwind from antipsychotic drug Vraylar helped Hungary’s Gedeon Richter to post a 40% leap in 2019 net profit. Analysts see more upside ahead for eastern Europe’s largest drugmaker.

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Biocon Pharma’s solid-dosage plant has received FDA inspection approval but its parent company was not so lucky, with one of its sites getting hit with five observations. Indoco, Strides, and Lupin were also in the regulatory spotlight while MedPharm has moved into a new, expanded facility and Coripharma has signed a packaging deal with Stada.

India’s Ajanta Pharma has announced what analysts called “blowout” third-quarter numbers following a string of weaker quarterly performances.

The US Food and Drug Administration has announced changes to how ANDAs are prioritized for review as it seeks to speed patient access to more affordable generic drugs and increase competition.

Bangladesh’s biggest pharmaceutical company, Beximco Pharmaceuticals, has posted a 16.7% jump in after-tax profit in its financial first half, powered by double-digit domestic and export revenue growth.